Close

Registration Now Open for the 14th Annual BIO World Congress on Industrial Biotechnology

Feb 8 2017
BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology.  The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada. 

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation

Jan 31 2017
Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal Organisms

Jan 18 2017
The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically engineered plants and plants and animals derived from certain newer precision breeding techniques, such as genome editing.

BIO’s Jim Greenwood Meets with India’s PM Modi

Jan 13 2017
Delivers Message: India Must Protects Innovators’ Work Product

BIO Statement on Proposed Maryland Drug Pricing Legislation

Jan 10 2017
BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.

BIO CEO & Investor Conference Programming Announced

Dec 15 2016
BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to discover trends in life sciences, network with peers and potential partners and explore investment opportunities. Established and emerging publicly traded and select private biotech companies are the focus of the event.

BIO Applauds Senate Passage of the 21st Century Cures Act

Dec 7 2016
Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:

BIO Applauds House Passage of the 21st Century Cures Act

Nov 30 2016
Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

BIO Responds to GAO Report Declaring RFS Will Not Meet Goals

Nov 29 2016
BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels but we would observe that EPA has chilled investment in commercializing this technology.

BIO Welcomes EPA’s Final 2017 Renewable Fuel Standards

Nov 23 2016
The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and cellulosic biofuels.